How The Allure Of Abivax Kept Marc de Garidel From The Beach
Lays Out Ambitious Plans
Abivax has had its ups and downs but newly appointed CEO Marc de Garidel tells Scrip he is confident that the French group is onto a winner with its ulcerative colitis drug, obefazimod.
